Who Paid My Doc
David Kronn
Clinical Genetics (M.D.) Valhalla, NY Medical Doctor
NPI 1619979697 CMS profile 1035959
503 Grasslands Rd, Ste 200, Valhalla, NY 10595
General payments
$134,590
Research payments
$12,814
Ownership & investment interest
$0
Research they led as principal investigator
$2,564,363
Through program year 2025, David Kronn of Valhalla, NY is reported in the CMS Open Payments database as having received $134,590 across 162 general payments and $12,814 in research payments paid to them. Separately, studies naming them as principal investigator received $2,564,363 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 95th percentile of Clinical Genetics (M.D.) profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,367 | 6 | |
| 2024 | General | $26,061 | 24 | |
| 2023 | General | $26,452 | 27 | |
| 2023 | Research | $1,000 | 3 | |
| 2022 | General | $24,291 | 26 | |
| 2022 | Research | $1,000 | 2 | |
| 2021 | General | $9,645 | 15 | |
| 2021 | Research | $2,750 | 5 | |
| 2020 | General | $15,316 | 17 | |
| 2020 | Research | $4,497 | 10 | |
| 2019 | General | $31,459 | 47 | |
| 2019 | Research | $3,567 | 10 |
Beside peers
- David Kronn
- Clinical Genetics (M.D.) median
- Middle half of Clinical Genetics (M.D.)
- National median
In program year 2025, general payments to David Kronn were reported at $1,367. Among 315 Clinical Genetics (M.D.) profiles paid that year, the median was $255 and the middle half received between $85 and $3,583.
Show as a table
| Year | David Kronn | Clinical Genetics (M.D.) median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $31,459 | $130 | $24–$2,691 | $163 |
| 2020 | $15,316 | $126 | $30–$3,700 | $114 |
| 2021 | $9,645 | $185 | $30–$3,777 | $132 |
| 2022 | $24,291 | $136 | $44–$2,749 | $149 |
| 2023 | $26,452 | $196 | $55–$5,220 | $160 |
| 2024 | $26,061 | $165 | $46–$3,171 | $164 |
| 2025 | $1,367 | $255 | $85–$3,583 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 4 drugsPart D claims
121
Drug cost
$816,091
Branded share of claims
26.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Sapropterin Dihydrochloride | Generic | 78 | $792,970 | |
| Potassium Chloride | Generic | 11 | $15,010 | |
| Cystagon Cysteamine Bitartrate | Brand | 11 | $4,578 | |
| Levocarnitine Levocarnitine (With Sugar) | Brand | 21 | $3,534 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero.
Billing to Medicare
Part B · data year 2024 · 6 billing codesPaid by Medicare
$4,994
Medicare patients
28
Services billed
48
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 57% | |
| Diabetes | 39% | |
| Arthritis | 39% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Payments and prescribing
First 5 of 7 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| XENPOZYME |
|
$9,175 | — | — |
| NEXVIAZYME |
|
$839 | — | — |
| POMBILITI |
|
$98 | — | — |
| OPFOLDA |
|
$98 | — | — |
| CERDELGA |
|
$28 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 7 in the dashboard with a free accountRecords
192 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Clinical Genetics (M.D.) in New York
Robert Desnick
Clinical Genetics (M.D.) · New York, NY
Manisha Balwani
Clinical Genetics (M.D.) · New York, NY
Jaya Ganesh
Clinical Genetics (M.D.) · New York, NY
Berrin Monteleone
Clinical Genetics (M.D.) · Mineola, NY
George Diaz
Clinical Genetics (M.D.) · New York, NY
Christopher Cunniff
Clinical Genetics (M.D.) · New York, NY
Related records
Clinical Genetics (M.D.) in New York
Practitioners in the same specialty and state, ranked by reported value.
All Clinical Genetics (M.D.)
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.